142 related articles for article (PubMed ID: 23737087)
21. A molecular perspective for the development of antibodies against the human respiratory syncytial virus.
Loaiza RA; Ramírez RA; Sepúlveda-Alfaro J; Ramírez MA; Andrade CA; Soto JA; González PA; Bueno SM; Kalergis AM
Antiviral Res; 2024 Feb; 222():105783. PubMed ID: 38145755
[TBL] [Abstract][Full Text] [Related]
22. Target Trial Emulation and Bias Through Missing Eligibility Data: An Application to a Study of Palivizumab for the Prevention of Hospitalization Due to Infant Respiratory Illness.
Tompsett D; Zylbersztejn A; Hardelid P; De Stavola B
Am J Epidemiol; 2023 Apr; 192(4):600-611. PubMed ID: 36509514
[TBL] [Abstract][Full Text] [Related]
23. Monoclonal antibody therapies in respiratory syncytial virus prophylaxis-An umbrella review.
Kuitunen I; Backman K; Gärdström E; Renko M
Pediatr Pulmonol; 2024 May; ():. PubMed ID: 38751021
[TBL] [Abstract][Full Text] [Related]
24. Rebuttal: palivizumab for the prevention of respiratory syncytial virus infection.
Smart KA; Lanctôt KL; Paes BA
Can Fam Physician; 2010 Oct; 56(10):988-91. PubMed ID: 20944037
[No Abstract] [Full Text] [Related]
25. RSVpreF (Abrysvo) and Nirsevimab-alip (Beyfortus) for the Prevention of Respiratory Syncytial Virus Infection.
Nodelman M; Scott AM
Am Fam Physician; 2024 Jun; 109(6):578-579. PubMed ID: 38905561
[No Abstract] [Full Text] [Related]
26. Daily intranasal palivizumab to prevent respiratory syncytial virus infection in healthy preterm infants: a phase 1/2b randomized placebo-controlled trial.
Mazur NI; Löwensteyn YN; Terstappen J; Leusen J; Schobben F; Cianci D; van de Ven PM; Nierkens S; Bont LJ;
EClinicalMedicine; 2023 Dec; 66():102324. PubMed ID: 38192587
[TBL] [Abstract][Full Text] [Related]
27. Respiratory syncytial virüs infections in neonates and infants.
Perk Y; Özdil M
Turk Pediatri Ars; 2018 Jun; 53(2):63-70. PubMed ID: 30116126
[TBL] [Abstract][Full Text] [Related]
28. Safety and pharmacokinetics of extended use of palivizumab in Saudi Arabian infants and children.
Al-Alaiyan S; Pollack P; Notario GF
Drugs Context; 2015; 4():. PubMed ID: 25767550
[TBL] [Abstract][Full Text] [Related]
29. Comparison of corticosteroids for treatment of respiratory syncytial virus bronchiolitis and pneumonia in cotton rats.
Ottolini MG; Curtis SJ; Porter DD; Mathews A; Richardson JY; Hemming VG; Prince GA
Antimicrob Agents Chemother; 2002 Jul; 46(7):2299-302. PubMed ID: 12069994
[TBL] [Abstract][Full Text] [Related]
30. The Loss of Respiratory Syncytial Virus Seasonality and the Effects on Palivizumab Administration.
Tan D; Goff Z; MacDonald B; Blyth CC; Foley DA
Pediatr Infect Dis J; 2022 Sep; 41(9):e407-e408. PubMed ID: 35763694
[No Abstract] [Full Text] [Related]
31. Emerging drugs for respiratory syncytial virus infection.
Olszewska W; Openshaw P
Expert Opin Emerg Drugs; 2009 Jun; 14(2):207-17. PubMed ID: 19453286
[TBL] [Abstract][Full Text] [Related]
32. Respiratory syncytial virus-approved mAb Palivizumab as ligand for anti-idiotype nanobody-based synthetic cytokine receptors.
Ettich J; Wittich C; Moll JM; Behnke K; Floss DM; Reiners J; Christmann A; Lang PA; Smits SHJ; Kolmar H; Scheller J
J Biol Chem; 2023 Nov; 299(11):105270. PubMed ID: 37734558
[TBL] [Abstract][Full Text] [Related]
33. Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands.
Whelan B; Musters E; Murray A; Moore E; Lievaart L; Visser S; Toxopeus E; van Veen A; Notario G; Campbell FJ
Drugs Ther Perspect; 2016; 32():119-130. PubMed ID: 26924927
[TBL] [Abstract][Full Text] [Related]
34. Behavioural interventions to increase adherence to palivizumab prophylaxis in children with CHD.
Erolu E; Kıbrıs Ö; Tosun Y; Yildirim A; Pamukcu O; Basar EZ; Babaoglu K; Epcacan S; Donmez Y; Giray D; Dervisoglu P; Tascı O
Cardiol Young; 2024 Apr; ():1-8. PubMed ID: 38664919
[TBL] [Abstract][Full Text] [Related]
35. Preventing hospitalizations for respiratory syncytial virus infection.
Robinson JL; Le Saux N;
Paediatr Child Health; 2015; 20(6):321-33. PubMed ID: 26435673
[TBL] [Abstract][Full Text] [Related]
36. Improving Palivizumab Administration to High-Risk Infants with Heart Disease via a Communication-Based Quality Improvement Initiative.
Leone DM; Rodriguez A; Cowenhoven K; O'Connell M; Grossman M; Ferdman D
Pediatr Cardiol; 2024 Feb; ():. PubMed ID: 38300318
[TBL] [Abstract][Full Text] [Related]
37. Respiratory syncytial virus outbreak in neonatal intensive care unit: Impact of infection control measures plus palivizumab use.
Silva Cde A; Dias L; Baltieri SR; Rodrigues TT; Takagi NB; Richtmann R
Antimicrob Resist Infect Control; 2012 May; 1(1):16. PubMed ID: 22958306
[TBL] [Abstract][Full Text] [Related]
38. Palivizumab and respiratory syncytial virus immune globulin intravenous for the prophylaxis of respiratory syncytial virus infection in high risk infants.
joint statement with the Fetus and Newborn Committee
Paediatr Child Health; 1999 Oct; 4(7):474-89. PubMed ID: 20212962
[No Abstract] [Full Text] [Related]
39. Opinion: The optimal use of risk factors to guide palivizumab prophylaxis against severe respiratory syncytial virus infection in moderate-to-late preterm infants.
Paes B; Lanari M; Rodgers-Gray B; Fullarton J; Carbonell-Estrany X
Front Pediatr; 2024; 12():1343960. PubMed ID: 38283631
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
